Toll Free: 1-888-928-9744
Published: Dec, 2015 | Pages:
59 | Publisher: Global Markets Direct
Industry: Pharmaceuticals & Healthcare | Report Format: Electronic (PDF)
Salivary Gland Cancer - Pipeline Review, H2 2015 Summary Global Markets Direct's, 'Salivary Gland Cancer - Pipeline Review, H2 2015', provides an overview of the Salivary Gland Cancer's therapeutic pipeline. This report provides comprehensive information on the therapeutic development for Salivary Gland Cancer, complete with comparative analysis at various stages, therapeutics assessment by drug target, mechanism of action (MoA), route of administration (RoA) and molecule type, along with latest updates, and featured news and press releases. It also reviews key players involved in the therapeutic development for Salivary Gland Cancer and special features on late-stage and discontinued projects. Global Markets Direct's report features investigational drugs from across globe covering over 20 therapy areas and nearly 3,000 indications. The report is built using data and information sourced from Global Markets Direct's proprietary databases, Company/University websites, SEC filings, investor presentations and featured press releases from company/university sites and industry-specific third party sources, put together by Global Markets Direct's team. Drug profiles/records featured in the report undergoes periodic updation following a stringent set of processes that ensures that all the profiles are updated with the latest set of information. Additionally, processes including live news & deals tracking, browser based alert-box and clinical trials registries tracking ensure that the most recent developments are captured on a real time basis. The report enhances decision making capabilities and help to create effective counter strategies to gain competitive advantage. It strengthens R&D pipelines by identifying new targets and MOAs to produce first-in-class and best-in-class products. Note*: Certain sections in the report may be removed or altered based on the availability and relevance of data for the indicated disease. Scope - The report provides a snapshot of the global therapeutic landscape of Salivary Gland Cancer - The report reviews key pipeline products under drug profile section which includes, product description, MoA and R&D brief, licensing and collaboration details & other developmental activities - The report reviews key players involved in the therapeutics development for Salivary Gland Cancer and enlists all their major and minor projects - The report summarizes all the dormant and discontinued pipeline projects - A review of the Salivary Gland Cancer products under development by companies and universities/research institutes based on information derived from company and industry-specific sources - Pipeline products coverage based on various stages of development ranging from pre-registration till discovery and undisclosed stages - A detailed assessment of monotherapy and combination therapy pipeline projects - Coverage of the Salivary Gland Cancer pipeline on the basis of target, MoA, route of administration and molecule type - Latest news and deals relating related to pipeline products Reasons To Buy - Provides strategically significant competitor information, analysis, and insights to formulate effective R&D development strategies - Identify emerging players with potentially strong product portfolio and create effective counter-strategies to gain competitive advantage - Develop strategic initiatives by understanding the focus areas of leading companies - Identify and understand important and diverse types of therapeutics under development for Salivary Gland Cancer - Plan mergers and acquisitions effectively by identifying key players of the most promising pipeline - Devise corrective measures for pipeline projects by understanding Salivary Gland Cancer pipeline depth and focus of Indication therapeutics - Develop and design in-licensing and out-licensing strategies by identifying prospective partners with the most attractive projects to enhance and expand business potential and scope - Modify the therapeutic portfolio by identifying discontinued projects and understanding the factors that drove them from pipeline
Table of Contents
Table of Contents 2 List of Tables 4 List of Figures 4 Introduction 5 Global Markets Direct Report Coverage 5 Salivary Gland Cancer Overview 6 Therapeutics Development 7 Pipeline Products for Salivary Gland Cancer - Overview 7 Pipeline Products for Salivary Gland Cancer - Comparative Analysis 8 Salivary Gland Cancer - Therapeutics under Development by Companies 9 Salivary Gland Cancer - Therapeutics under Investigation by Universities/Institutes 10 Salivary Gland Cancer - Pipeline Products Glance 11 Clinical Stage Products 11 Salivary Gland Cancer - Products under Development by Companies 12 Salivary Gland Cancer - Products under Investigation by Universities/Institutes 13 Salivary Gland Cancer - Companies Involved in Therapeutics Development 14 AstraZeneca Plc 14 Bayer AG 15 Ignyta, Inc. 16 Loxo Oncology, Inc. 17 Otsuka Holdings Co., Ltd. 18 Plexxikon Inc. 19 Salivary Gland Cancer - Therapeutics Assessment 20 Assessment by Monotherapy Products 20 Assessment by Target 21 Assessment by Mechanism of Action 23 Assessment by Route of Administration 25 Assessment by Molecule Type 27 Drug Profiles 29 AZD-5312 - Drug Profile 29 Product Description 29 Mechanism of Action 29 R&D Progress 29 Cellular Immunotherapy for Oncology - Drug Profile 30 Product Description 30 Mechanism of Action 30 R&D Progress 30 entrectinib - Drug Profile 32 Product Description 32 Mechanism of Action 32 R&D Progress 32 LOXO-101 - Drug Profile 34 Product Description 34 Mechanism of Action 34 R&D Progress 34 OPB-111001 - Drug Profile 36 Product Description 36 Mechanism of Action 36 R&D Progress 36 pexidartinib - Drug Profile 37 Product Description 37 Mechanism of Action 37 R&D Progress 37 regorafenib - Drug Profile 39 Product Description 39 Mechanism of Action 39 R&D Progress 39 Salivary Gland Cancer - Recent Pipeline Updates 43 Salivary Gland Cancer - Dormant Projects 56 Salivary Gland Cancer - Discontinued Products 57 Appendix 58 Methodology 58 Coverage 58 Secondary Research 58 Primary Research 58 Expert Panel Validation 58 Contact Us 58 Disclaimer 59
List of Tables
Number of Products under Development for Salivary Gland Cancer, H2 2015 7 Number of Products under Development for Salivary Gland Cancer - Comparative Analysis, H2 2015 8 Number of Products under Development by Companies, H2 2015 9 Number of Products under Investigation by Universities/Institutes, H2 2015 10 Comparative Analysis by Clinical Stage Development, H2 2015 11 Products under Development by Companies, H2 2015 12 Products under Investigation by Universities/Institutes, H2 2015 13 Salivary Gland Cancer - Pipeline by AstraZeneca Plc, H2 2015 14 Salivary Gland Cancer - Pipeline by Bayer AG, H2 2015 15 Salivary Gland Cancer - Pipeline by Ignyta, Inc., H2 2015 16 Salivary Gland Cancer - Pipeline by Loxo Oncology, Inc., H2 2015 17 Salivary Gland Cancer - Pipeline by Otsuka Holdings Co., Ltd., H2 2015 18 Salivary Gland Cancer - Pipeline by Plexxikon Inc., H2 2015 19 Assessment by Monotherapy Products, H2 2015 20 Number of Products by Stage and Target, H2 2015 22 Number of Products by Stage and Mechanism of Action, H2 2015 24 Number of Products by Stage and Route of Administration, H2 2015 26 Number of Products by Stage and Molecule Type, H2 2015 28 Salivary Gland Cancer Therapeutics - Recent Pipeline Updates, H2 2015 43 Salivary Gland Cancer - Dormant Projects, H2 2015 56 Salivary Gland Cancer - Discontinued Products, H2 2015 57
Speak to the report author to design an exclusive study to serve your research needs.
Your personal and confidential information is safe and secure.